Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

7.133 +0.363 (+5.36%)
Streaming Delayed Price Updated: 2:46 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
41 42 Next >
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment
Via Investor Brand Network
News headline image
Psychedelic Drug Stocks Index Up Last Week, Still Down YTD ↗
The psychedelic Compounds-Based Drug Stocks Index was +24.0% last week; +33.5% in the last 5 weeks; but still -44.0% YTD. 
Via Talk Markets
News headline image
Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Clinilabs Drug Development Corporation
Via Business Wire
News headline image
Psychedelic Stock Gainers And Losers From July 11, 2022 ↗
GAINERS: Allied (OTC:ALID) shares closed up 14.67% at $0.54 
Via Benzinga
Congressional Leaders Want Studies to be Conducted on Mental Health Benefits of Psychedelics
Via Investor Brand Network
Topics Law Enforcement
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004
Via Investor Brand Network
News headline image
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
From Cybin Inc.
Via Business Wire
News headline image
Allied, GH Research Among Top Psychedelic Movers Of Today ↗
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 9.74% at $12.85 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From July 7, 2022 ↗
GAINERS: Allied (OTC:ALID) shares closed up 14.62% at $0.54 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From July 6, 2022 ↗
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 20.50% at $0.89 
Via Benzinga
Archaeologists Believe Hidden Andean Passageways Were Most Likely Used During Psychedelic Rituals
Via Investor Brand Network
News headline image
Numinus Wellness, Mind Medicine Among Top Psychedelic Movers Of Today ↗
GAINERS: Numinus Wellness (OTC:NUMIF) shares closed up 13.88% at $0.20 
Via Benzinga
New Study Finds That Probiotics May Be Useful in Fight Against Depression
Via Investor Brand Network
News headline image
Psychedelic Stock Gainers And Losers From July 1, 2022 ↗
GAINERS: Allied (OTC:ALID) shares closed up 4.17% at $0.50 
Via Benzinga
News headline image
June Update: Psychedelic Compounds-Based Drug Stocks Index Up 8%; Down 55% YTD ↗
The psychedelic Compounds-Based Drug Stocks Index was up 7.7% in June but is still down 54.9% YTD. 
Via Talk Markets
News headline image
Psychedelic Stock Gainers And Losers From June 30, 2022 ↗
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.44% at $10.82 
Via Benzinga
News headline image
Seelos Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today ↗
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 6.77% at $0.69 
Via Benzinga
NJ Senate President Introduces Psilocybin Legalization Bill Containing Home-Cultivation Provision
Via Investor Brand Network
Topics Cannabis
News headline image
GH Research, Numinus Wellness Among Top Psychedelic Movers Of Today ↗
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 3.03% at $0.85 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Adelia Announce Achievement of Milestone
Via Investor Brand Network
News headline image
Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder ↗
Psychedelic biopharma company Cybin Inc. (NEO: CYBN) has received FDA Investigational New Drug Application (IND) approval for a Phase 1/2a clinical trial evaluating its proprietary CYB003 for treating... 
Via Benzinga
News headline image
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
News headline image
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today ↗
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 3.12% at $0.82 
Via Benzinga
News headline image
Rebalanced Psychedelic Compounds-Based Drug Stocks Index Down 52.7% YTD ↗
The Psychedelic Compounds-Based Drug Stocks Index is down 52.7% YTD and down 75.9% from its highest point in 2021. 
Via Talk Markets
Why More Attention Needs to Be Paid to Paternal Mental Health
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moving Forward with Phase 1/2a Clinical Trial after Receiving Key FDA Approval
Via Investor Brand Network
News headline image
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
News headline image
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today ↗
GAINERS: Allied (OTC:ALID) shares closed up 29.44% at $0.56 
Via Benzinga
New Netflix Series to Explore the Use of Psychedelics for Mental Health
Via Investor Brand Network
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.